A larger clinical trial involving 500 patients with mild to moderate AD revealed that rosiglitazone treatment resulted in a significant improvement in cognition in patients without ε4 allele of the apolipoprotein E (APOE-ε4) gene whereas patients with the APOE-ε4 showed no alterations in the cognitive tests [267]. Here, APOE is linked to Alzheimer disease.